Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer-Reference-Cited by-同舟云学术

Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer

Published:2020-09-29 Issue:22 Volume:9 Page:8406-8411
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Tfayli Arafat¹^ORCID,Al Assaad Majd¹,Fakhri Ghina¹,Akel Reem¹,Atwi Hanine¹,Ghanem Hady²,El Karak Fadi³,Farhat Fadi⁴,Al Rabi Kamal⁵,Sfeir Pierre⁶,Youssef Pierre⁷,Mansour Ziad⁸,Assi Hazem¹^ORCID,Haidar Mohamad⁹,Abi Ghanem Alain⁹,Khalifeh Ibrahim¹⁰,Boulos Fouad¹⁰,Mahfouz Ramy¹⁰,Youssef Bassem¹¹,Zeidan Youssef¹¹,Bejjany Rachelle¹,Khuri Fadlo¹

Affiliation:

1. Division of Hematology‐Oncology American University of Beirut Medical Center Beirut Lebanon

2. Department of Internal Medicine Lebanese American University Medical Center‐Rizk Hospital Beirut Lebanon

3. Department of Internal Medicine Saint Joseph University Beirut Lebanon

4. Division of Hematology‐Oncology Hammoud Hospital University Medical Center Saida Lebanon

5. Department of Internal Medicine King Hussien Cancer Center Amman Jordan

6. Division of Cardiothoracic Surgery American University of Beirut Medical Center Beirut Lebanon

7. Division of Cardiothoracic Surgery Hammoud Hospital University Medical Center Saida Lebanon

8. Division of Cardiothoracic Surgery Geitaoui Medical Center Beirut Lebanon

9. Department of Radiology American University of Beirut Medical Center Beirut Lebanon

10. Department of Pathology American University of Beirut Medical Center Beirut Lebanon

11. Department of Radiation Oncology American University of Beirut Medical Center Beirut Lebanon

Funder

Merck KGaA

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3456

Reference18 articles.

1. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

2. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

3. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

4. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

5. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis;Cancers;2024-07-08

2. Cancer research in Lebanon: Scope of the most recent publications of an academic institution (Review);Oncology Letters;2024-06-03

3. Efficacy and safety of different cycles of neoadjuvant immunotherapy in resectable non-small cell lung cancer: A systematic review and meta-analysis;Heliyon;2024-06

4. Neoadjuvant Chemoimmunotherapy for NSCLC;JAMA Oncology;2024-05-01

5. Incidence of thromboembolic events in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis;Journal of Cancer Research and Therapeutics;2024-04